BreezeBio Raises $60M Series B to Advance Precision Genetic Medicines

Team S · 2026-02-28T13:05:26.000Z

U.S.-based biotechnology startup BreezeBio has secured $60 million in a Series B funding round to accelerate the development of its next-generation genetic medicines targeting autoimmune diseases and oncology. The company is focused on creating advanced therapies that deliver genetic payloads precisely to targeted cells, aiming to improve treatment outcomes for complex diseases. BreezeBio, formerly known as GenEdit, is building a new class of therapeutics powered by its proprietary NanoGalaxy platform, a non-viral nanoparticle system designed to deliver genetic payloads such as mRNA to specific tissues including immune, cardiac, pulmonary, and central nervous system cells. The platform addresses one of the biggest challenges in gene therapy - targeted delivery enabling the development of more precise genetic medicines. The $60 million Series B round was led by Yuanta Investment and DSC Investment, with participation from SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, along with existing investors DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners. The new funding will support the advancement of BreezeBio’s internal therapeutic programs and further expand its NanoGalaxy genetic medicine delivery platform. The company’s lead candidate, BRZ-101, is designed to restore immune tolerance in type 1 diabetes by delivering mRNA-encoded autoantigens to immune cells, helping retrain the immune system to stop attacking insulin-producing cells. BreezeBio is currently advancing the therapy into IND-enabling studies ahead of clinical trials. Beyond its internal pipeline, BreezeBio also maintains a multi-year collaboration and licensing agreement with Genentech, a member of the Roche Group, providing additional validation for its technology platform.

Member Login Get Access

BreezeBio Raises $60M Series B to Advance Precision Genetic Medicines | Newnex